Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study
Authors:
Top Cited Papers
Open Access
- 6 May 2023
- journal article
- research article
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 13 (3) , 407-421
Abstract
Importance: Both the morbidity and mortality of prostate cancer are increasing worldwide. Updated evaluations of prostate cancer burden and its global, regional and national patterns are essential for formulating effective preventive strategies. Objective: To investigate prostate cancer incidence, mortality, and disability-adjusted life years (DALYs) between 1990 and 2019 to facilitate preventive measures and control planning. Methods: Annual incident cases, deaths, DALYs, age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized DALYs rates (ASDRs) of prostate cancer between 1990 and 2019 were derived from the Global Burden of Diseases study 2019. Percentage changes in incident cases, deaths and DALYs and estimated annual percentage changes (EAPCs) in ASIRs, ASMRs and ASDRs were calculated to quantify temporal trends. Correlations between EAPCs and socio-demographic index (SDI) and universal health coverage index (UHCI) were evaluated by Pearson correlation analyses. Results: Globally, the number of incident cases, deaths, and DALYs of prostate cancer increased by 116.11%, 108.94%, and 98.25% from 1990 to 2019, respectively. The ASIR increased by an average of 0.26% (95% CI: 0.14%, 0.37%) per year between 1990 and 2019, while the ASMR and ASDR decreased by an average of – 0.75% (95% CI: – 0.84%, – 0.67%) and – 0.71% (95% CI: – 0.78%, – 0.63%) per year in this period, respectively. Epidemic trends in the burdens of prostate cancer were not uniform throughout different groups of SDI or geography. The burdens of prostate cancer varied across SDI regions, with an increasing trend in ASIR, ASMR, and ASDR in low and low-middle SDI regions between 1990 and 2019. A significant positive correlation between the EAPC in ASIR and UHCI was observed in countries with a UHCI < 70 (ρ = 0.37, p < 0.001). Interpretation: Prostate cancer remains a major global health burden due to the increase in incident cases, deaths, and DALYs in the past three decades. These increases are likely to continue as the population ages, which indicates a potential talent gap in the trained healthcare workforce. The diversity of prostate cancer development models implies the importance of specific local strategies tailored for each country’s risk factor profile. Prevention, early detection and more effective treatment strategies for prostate cancer are essential.Keywords
Funding Information
- Prostate Cancer Foundation (13YOUN14)
- Peking University People's Hospital (RDY2019-19)
This publication has 28 references indexed in Scilit:
- Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU)European Urology Focus, 2019
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate CancerEuropean Urology, 2019
- Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialCancer, 2019
- The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer preventionJournal of Hepatology, 2019
- Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer MortalityJAMA, 2018
- The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer PredictionJournal of Urology, 2017
- Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 CountriesEuropean Urology, 2016
- Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesJAMA Oncology, 2016
- Time Trends in Histological Features of Latent Prostate Cancer in JapanJournal of Urology, 2016
- Screening for Prostate Cancer With the Prostate-Specific Antigen TestJAMA, 2014